

Corporate Action Notice

June 24, 2016

Reverse Stock Split

Singulus Technologies

CUSIP: 829334101 / **ISIN:** US8293341017

DR Ticker Symbol: SGTSY

Ratio: (DRs: Underlying Share): 2:1

Please be advised that Singulus Technologies has announced a reverse stock split of one (1) new share for every one hundred and sixty (160) existing shares.

As a result, BNY Mellon will effect a reverse stock split on the Singulus Technologies Depositary Receipt ("DR") program. Effective July 5, 2016, DR holders of Singulus Technologies are required on a mandatory basis to surrender their DR(s) to BNY Mellon for cancellation and exchange to receive one (1) "New" Depositary Share ("DS") (CUSIP 829334200) for every one hundred and sixty (160) "Old" DSs (CUSIP 829334101). Holders of DSs in brokerage accounts will have their DRs automatically exchanged and need not take any action. No fraction of a DS will be issued. BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds to DR holders.

The existing ratio of two (2) Depositary Shares representing one (1) ordinary share will remain the same.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATE AND RATES FOR THIS CORPORATE ACTION:

Effective Date: July 5, 2016

Exchange Rate: 1 New DS for every 160 old DSs

Old CUSIP: 829334101

New CUSIP: 829334200

Cancellation Fee per DS: \$0.00

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK

Ravi Davis
Richard J Maehr
+ 1 212 815 2267
adrdesk@bnymellon.com

LONDON

Jacek Jankowski
Vice President
+ 44 207 163 7427
jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file703_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



BNY MELLON